Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 2/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | CASP7 | P55210 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394300 | 0.73 | TAAR1 (0.76) | TAAR1ALDH1A1KDM4EHPGDPOLB | |
| SCHEMBL244155 | 0.71 | — | — | |
| SCHEMBL30487922 | 0.71 | TAAR1 (0.73) | TAAR1ALDH1A1KDM4EHPGDPOLB | |
| SCHEMBL19662062 | 0.71 | TAAR1 (0.58) | TAAR1ALDH1A1KDM4EHPGDPOLB | |
| SCHEMBL7260786 | 0.70 | POLB (0.52) | TAAR1ALDH1A1KDM4EHPGDPOLB | |
| SCHEMBL7102498 | 0.69 | TAAR1 (0.42) | TAAR1ALDH1A1KDM4EHPGDPOLB | |
| SCHEMBL1423819 | 0.69 | TAAR1 (0.47) | TAAR1ALDH1A1KDM4EHPGDPOLB | |
| SCHEMBL3691479 | 0.69 | CYP1A2 (0.46) | ALDH1A1KMT2A | |
| SCHEMBL1799678 | 0.69 | ALDH1A1 (0.63) | TAAR1ALDH1A1KDM4EHPGDPOLB | |
| SCHEMBL162083 | 0.69 | TAAR1 (0.62) | TAAR1ALDH1A1KDM4EHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515433-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2019-07-31 | — | — | EP | disclosed |
| US-10166215-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-01-01 | — | — | US | disclosed |
| US-9999616-B2 | — | — | 2018-06-19 | — | — | US | disclosed |
| WO-2018056854-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2018-03-29 | — | — | WO | disclosed |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-7470722-B2 | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470722-B2 | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| WO-2005123089-A2 | MULTICYCLIC SULFONAMIDE COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| EP-1363639-A1 | PYRROLO 2,3-d]PYRIMIDINE AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002055084-A1 | PYRROLO[2,3-d]PYRIMIDINE AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10166215-B2 | Substituted bicyclic compounds as bromodomain inhibitors | BRD4, BRD3, BRD2 | TAAR1 2701/4885ALDH1A1 4472/4885KDM4E 209/4885 |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | TAAR1 2588/4885ALDH1A1 4515/4885KDM4E 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.